We bring together early patient identification, centralized pathology oversight, and targeted referral coordination across key lupus nephritis markets to ensure the right patients reach the right sites at the right time. The result is lower enrollment risk, greater diagnostic confidence, and stronger protection of primary endpoint integrity.
We’ll connect you with the right rare nephrology clinical development team.
Why Lupus Nephritis Programs Demand Specialized Support
At Worldwide, we treat enrollment timing in lupus nephritis as a function of protocol design and patient access, not site count alone. With experience across pivotal programs in 30 countries and over 240 sites, we leverage early flare detection, centralized pathology review, and language-matched referral coordination to identify eligible patients sooner and keep recruitment on track in competitive study environments.
Lupus nephritis flares are episodic and patients often feel well between them. The window in which a patient is both eligible and reachable can close before a site knows.
Biopsy interpretation, serological criteria, and eligibility documentation vary across global sites, and that variability surfaces at endpoint analysis rather than at trial entry.
Lupus nephritis concentrates in populations outside North America and Western Europe, which puts referral coordination, language and travel logistics on the critical path rather than at the margins.

Partnership & Approach
We ensure our Sponsors have easy access to senior scientific, medical, and project leaders who co-chair our renal portfolio and are empowered to make decisions without unnecessary escalation. For lupus nephritis programs, where every enrollment opportunity depends on flare timing and diagnostic precision, having the same experienced leaders involved from strategy through execution preserves momentum, reduces operational friction, and keeps programs moving forward.
A pivotal Phase III delivered on time in a crowded recruitment field, through natural disasters that compromised site performance mid-study.
Why Worldwide for Lupus Nephritis Trials
Urine dipsticks for patient self-monitoring, disease surveillance and pre-screening chart review surface eligible patients while the enrolment window is open, supporting treatment initiation at symptom onset.
Biopsy interpretation and eligibility documentation reviewed centrally across light microscopy, electron microscopy and immunofluorescence, so the trial-entry diagnosis holds through regulatory submission.
International patient travel and pre-qualification handled by language-matched, medically trained coordinators, alongside home health, concierge travel and patient navigator services.
Frequently Asked Questions
We have answered the questions sponsors ask most often about lupus nephritis programs. If yours isn’t here, our rare nephrology team is happy to help.
In lupus nephritis, recruitment depends on finding patients while the enrollment window is still open. Because patients often feel well between flares, those opportunities can be missed until disease activity escalates and urgent care is required. Through proactive disease surveillance, patient education programs, and home urine dipstick monitoring for proteinuria, we help surface eligible patients earlier, connecting patients with care while they remain eligible and before disease progression leads to emergency intervention.
Central pathology review is integrated at the protocol level, covering light microscopy, electron microscopy, and immunofluorescence. Biopsy interpretation and eligibility documentation are managed consistently across every site and country, so the trial-entry diagnosis holds through regulatory submission. In an indication where classification drives both eligibility and the primary endpoint, that consistency is what protects the analysis.
Lupus nephritis populations concentrate outside North America and Western Europe. Worldwide coordinates international patient travel and pre-qualification through language-matched, medically trained coordinators, so referrals arrive at screening without language or logistics slowing them down. Home health, concierge travel and patient navigator services sit alongside that for patients traveling long distances.
Yes. On the pivotal Phase III lupus nephritis study, natural disasters threatened site participation mid-trial. Trial-naive sites were identified, trained and activated quickly to replace compromised capacity, enrollment was met ahead of schedule and database lock was delivered on time.
24-hour and first morning void collections carry much of the dropout risk in renal trials. We support them with non-spoken instructional videos, male and female collection containers, cooler backpacks for confidential transport, and at-home sample pickup where it can be arranged, alongside home health and patient navigator services.
Active comparators have replaced placebo controls in most new lupus nephritis programs, and proteinuria reduction is an accepted accelerated approval surrogate with eGFR slope confirming over 24 months. Endpoint strategy, designation opportunities and KOL engagement go into protocol design from the start rather than after the first regulatory meeting.